Wang Xianhui, Kokabee Leila, Kokabee Mostafa, Conklin Douglas S
Department of Biomedical Sciences, Cancer Research Center, State University of New York, Rensselaer, NY, United States.
Front Cell Dev Biol. 2021 Jul 8;9:668996. doi: 10.3389/fcell.2021.668996. eCollection 2021.
Bruton's tyrosine kinase (BTK) is a soluble tyrosine kinase with central roles in the development, maturation, and signaling of B cells. BTK has been found to regulate cell proliferation, survival, and migration in various B-cell malignancies. Targeting BTK with recently developed BTK inhibitors has been approved by the Food and Drug Administration (FDA) for the treatment of several hematological malignancies and has transformed the treatment of several B-cell malignancies. The roles that BTK plays in B cells have been appreciated for some time. Recent studies have established that BTK is expressed and plays pro-tumorigenic roles in several epithelial cancers. In this review, we focus on novel isoforms of the BTK protein expressed in epithelial cancers. We review recent work on the expression, function, and signaling of these isoforms and their value as potential therapeutic targets in epithelial tumors.
布鲁顿酪氨酸激酶(BTK)是一种可溶性酪氨酸激酶,在B细胞的发育、成熟和信号传导中起核心作用。已发现BTK在各种B细胞恶性肿瘤中调节细胞增殖、存活和迁移。用最近开发的BTK抑制剂靶向BTK已获美国食品药品监督管理局(FDA)批准用于治疗多种血液系统恶性肿瘤,并改变了几种B细胞恶性肿瘤的治疗方式。BTK在B细胞中所起的作用已为人所知有一段时间了。最近的研究证实,BTK在上皮癌中表达并发挥促肿瘤作用。在本综述中,我们重点关注上皮癌中表达的BTK蛋白的新亚型。我们回顾了关于这些亚型的表达、功能和信号传导及其作为上皮肿瘤潜在治疗靶点的价值的最新研究成果。